MAIL MAN

[righty]

Breaking News Alert - OTCBB: RMCP
Mon, December 14, 2009 6:53:59 AMFrom: Market Pulse <[e-mail]>Add to Contacts



--------------------------------------------------------------------------------



Welcome to Market Pulse's online newsletter. Market Pulse is a small-cap investor's first stop Web page. Each month, our user-friendly Web site profiles new and emerging companies that have excellent potential. We also feature quotes, charts, SEC filings, news headlines, previous profiles of featured companies and other valuable information that is easily accessed. We recommend that anyone investing perform his or her own due diligence.

Market Pulse is pleased to introduce Revolutions Medical Corporation (OTCBB: RMCP) to the investment community! Stay Tuned For Frequent Updates at www.market-pulse.com.

Revolutions Medical Corporation (OTCBB: RMCP) (RevMed) is engaged in the design, development, commercialization and acquisition of new products and tools to make healthcare safer and less expensive. RevMed's products include safety-engineered medical devices (SEMDs) and the flagship RevVac safety syringe (FDA Approved), safety blood drawing devices, and safety IV catheters. The products use a proprietary patented technology in which a vacuum causes the needle to retract into the barrel of the syringe or device after an injection is administered or blood is drawn. RevMed owns the patents to manufacture the disposable retractable syringe and phlebotomy device. The world market for SEMDs is projected to exceed $2 billion this year and is forecasted to maintain a 20% annual growth rate in the near term. RevMed also offers RevColor, RevDisplay and Rev3D, software solutions and proprietary tools that are compatible with standard MRIs and standard PACS. The software includes sorting of images, color, 3D, and automatic segmentation of images. These tools will enhance the physician's diagnostic confidence in an industry that is growing at 10% - 15% (more than 25 million procedures) per year with a worldwide market potential for these tools that exceeds $3.5 billion. The company is continually looking for new and improved technology through internal product development and acquisition. The company's future growth will be powered by new product line introductions, and the material expansion of existing successful lines. RevMed's Breast Biopsy System (BBS), stereotactic (minimally invasive) image-based localization technology, is one of those product lines pursuing the $9.5 billion breast screening industry. RevMed's Breast Biopsy System, the MRI enhancement software and the SEMDs will be launching in the next 18 months. All three markets are immediately addressable and total more than $14 billion. RevMed recently introduced its proprietary suite of MRI software products at the Radiology Society of North America annual meeting with great success. Radiologists and universities world-wide received presentations at the RMCP booth. A number of these contacts could play an important role in the company's ongoing efforts to clinically validate specific applications of its MRI tools prior to the 2010 commercial launch. Never has health care been a hotter issue, and the focus of the conversation is on increased safety at dramatically reduced cost. Revolutions Medical has the formula for success, and one that has them immediately positioned for a high growth future. With 3 recurring revenue business lines with blended gross margins projected to exceed 50% and anticipated profitability in its first full year of operations, Revolutions Medical Corporation is poised to become a significant player in the healthcare and medical devices industry!




Press Release

Source: Revolutions Medical Corporation

RevMed Hits Primary Milestone, Launches RevVac Mass Manufacturing Process

Achieves Goal of Q4 '09 Manufacturing Launch; Remains on Pace to Hit '10 Sales Projections

CHARLESTON, SC--(Marketwire - 12/14/09) - Revolutions Medical Corporation (RevMed) (OTCBB: RMCP), producers of the RevVac safety syringe, RevColor, RevDisplay and Rev3D MRI Technology, today announced that it has initiated the mass manufacturing process for the RevVac safety syringe, which is already FDA approved. By hitting its primary milestone, RevMed satisfies its previously announced commitment to begin production in Q4 '09. It also stays on pace to meet its Q2 '10 sales launch goal and $14.8 million 2010 revenue projection.

"After years in developing what we believe is the world's best safety syringe, we are extremely pleased to announce that the plan is now reality -- we have launched the mass manufacturing process for the RevVac safety syringe," stated Revolutions Medical CTO Richard Theriault. "This constitutes the next step toward full scale high volume production and commercialization. With this first phase we will 1) provide market-ready samples and 2) complete the steps necessary to ensure ultimate delivery of a high quality, high volume manufacturing solution. We have been working closely with the team at Goddard Technologies (www.goddardtech.com) -- the group responsible for the recent crucial product refinements -- towards this, our primary pre-sales milestone. We remain precisely on pace with our stated goals, and we can now demonstrate tangible progress toward bringing the much-anticipated RevVac to market in Q2 '10."

Andrew Goddard, President of Goddard Technologies, stated, "We are pleased to be working with Revolutions Medical on the first phase of the RevVac Safety Syringe mass manufacturing process. The RevVac design is unique and elegant as an easy to use, single-handed vacuum safety syringe. That we could contribute to a product of such high caliber is a source of great pride for Goddard Technologies."

About Revolutions Medical Corporation (www.revolutionsmedical.com)

RevMed's products include the RevVac safety syringe (FDA approved), safety blood drawing device and safety IV catheter. RevMed also provides RevColor, RevDisplay and Rev3D -- software solutions and proprietary tools that are compatible with standard MRIs and standard PACS. The software suite's functionality includes sorting of images, color, 3D and automatic segmentation of images.

Investor Resource Center

Fact Sheet: http://content.stockpr.com/rmcp/files/RMCP_-_Fact_Sheet_09-09-09.pdf

CEO Ron Wheet Audio Interview: http://ir.stockpr.com/revolutionsmedical/media-center/view/33

RevVac Demo Video: http://www.revolutionsmedical.com/videos/revac_directions_final.wmv

For additional information please call 800.290.8935 or visit www.market-pulse.com.

FORWARD-LOOKING STATEMENTS

The information contained herein includes forward-looking statements. These statements relate to future events or to our future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond our control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects our current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to our operations, results of operations, growth strategy and liquidity. We assume no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. The safe harbor for forward-looking statements contained in the Securities Litigation Reform Act of 1995 protects companies from liability for their forward-looking statements if they comply with the requirements of the Act.

Market Pulse All Rights Reserved.
© Copyright 2009
------------------------------------------------------------
Disclaimer/Disclosure

The publisher of this email is Market Pulse, which is an independent electronic online newsletter that is owned by Market Pulse LLC (MP).

Market Pulse (MP) is an investor or public relations firm which concentrates on promoting awareness among brokers, investors, and others in the investment community of small and micro-cap companies which otherwise have difficulty receiving coverage in the financial press. MP typically performs that service by profiling the companies on its Web sites, or by direct mailings to its database of members of the investment community.

Companies featured on Market Pulse's online newsletter pay consideration, which may include cash and/or shares of stock, to MP for dissemination of company information and, in some cases, for consulting services. When MP receives shares as compensation for investor relations, public relations, or consulting services for a featured company, MP may sell part or all of any such shares during the period in which MP is performing such services. MP's services for a company may cause the company's stock price to increase, in which event MP would make a profit when it sells its stock in the company. In addition, MP's selling of a company's stock may have a negative effect on the market price of the stock. All statements and expressions are the opinion of the companies featured and are not meant to be a solicitation or recommendation to buy, sell, or hold securities. MP is not a registered investment advisor or a broker dealer. While it is MP's goal to feature equity investments in micro or small capitalization companies that have the potential for long-term appreciation, investments in the companies reviewed are considered to be a high risk and use of the information provided is at the investor's sole risk. MP shall not be liable for any loss, damage, or expense of any kind resulting from the purchase of securities of a profiled company. MP may act as a consultant to the companies reviewed in this publication and may be remunerated by these companies or its shareholders for investor relation services.

Information contained herein is the opinion of MP and is intended to be used strictly for informational purposes. You should be aware that MP attempts to assure itself of the accuracy of the information contained in the analyses it publishes. In this regard, MP does, at times, rely on the accuracy of information supplied to it by the companies which are the subject of MP's analyses and/or parties related to those companies. MP also relies on the accuracy and integrity of information that is contained in company press releases and reports filed with the SEC. The companies mentioned in this publication have not approved the content or timing of the information being published unless otherwise noted. MP, because it relies on information supplied by various third parties disclaims any responsibility for the accuracy of such information. Any investor considering making an investment in any security which has been the subject of a MP analysis or opinion should, before making any such investment, consult with his/her market professional and/or do his/her own independent research regarding the company which is the subject of an MP opinion, recommendation or analysis. Information regarding companies which MP has opined upon is normally available from many sources including the subject company’s filings with the SEC and various press releases issued by the company.

The information that MP relies on is generally provided by the featured companies and also may include information from outside sources and interviews conducted by MP. While MP believes all sources of the information to be reliable, MP makes no representation or warranty as to the accuracy of the information provided. Investors should not rely solely on the information contained in this publication. Rather, investors should use the information contained in this publication as a starting point for doing additional independent research on the featured companies. Factual statements in this publication are made as of the date stated and are subject to change without notice. Nothing in this publication shall constitute a representation or warranty that there has been no change in the affairs of the company since the date of MP's profile of the company. MP and/or its officers, directors, or affiliates have received compensation for the dissemination of information on the companies which are the subject of profiles and/or may have, from time to time, a position in the securities with the intent to sell the securities mentioned herein. The profiles in the publication are believed to be reliable; however the publisher disclaims any and all liability as to the completeness or accuracy of the information contained in any profile and for any omissions of material facts from such profile. The profiles within this publication are not to be construed as offers to purchase securities in the companies which may be the subject of such profiles pursuant to federal or state law or the laws of any foreign jurisdiction. MP or MP's affiliates, agents, and/or relatives thereof may have interests or positions in equity securities of the companies reviewed in this email, some or all of which may have been acquired prior to the dissemination of this report, and may increase or decrease these positions at any time. MP has been compensated twenty five thousand restricted shares of Revolutions Medical Corporation by the company.

MP may be retained as a consultant for one to twelve months to companies that we feature. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor's investment may be lost or impaired due to the speculative nature of the companies profiled. We encourage our readers to invest carefully and read the investor information available at the web sites of the Securities and Exchange Commission ("SEC") at www.sec.gov and/or The Financial Industry Regulatory Authority ("FINRA") at www.finra.org.

Postal Address: Market Pulse, 4279 Roswell Road, Suite 102 #239, Atlanta, GA 30342.

To Unsubscribe, please click here.